EBGLYSS® makes progress in treating moderate to severe atopic dermatitis

Lebrikizumab is an investigational monoclonal antibody that binds to the IL-13 protein with high affinity and inhibits its signaling.

Almirall SA (BME:ALM) announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing authorization of EBGLYSS® (lebrikizumab) for the treatment of adults and adolescents (at least 12 years of age and… . + Read more

EMA accepts marketing authorization application for lebrikizumab to treat atopic dermatitis

The application to the EMA is based on results from the phase III studies ADvocate 1, 2 and ADhere. + read more

Atopic dermatitis, the world’s first chronic skin disease

In Spain, more than 2 million people currently suffer from this condition. + read more

Incidence of atopic dermatitis triples in young people

67% of adolescent patients have difficulty falling asleep, which is crucial for growth and development. + read more

Atraza® Advances in the treatment of atopic dermatitis

LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) is used to treat moderate to severe atopic dermatitis in adolescents. + read more

Dupilumab, also effective in severe subtypes of atopic dermatitis

In monotherapy or combination therapy, it can relieve symptoms and improve patients’ quality of life. + read more

Atopic dermatitis, more than just a skin pathology

Four out of 10 Madrid residents do not believe that atopic dermatitis affects sleep, self-esteem or stress. + read more

Source link

Leave a Comment